

Australian Centre for Disease Preparedness FMD Activities

Petrus Jansen van Vuren, Nagendrakumar Singanallur, Wilna Vosloo

CSIRO HEALTH AND BIOSECURITY/TRANSBOUNDARY ANIMAL DISEASES MITIGATION TEAM





Picture courtesy: Manda









SEACFMD-FAO Regional Experts Group

- Preparation of protocols for sample collection (nasal and oral swabs, probang samples)
- Preparation of an algorithm for genomic identification and characterisation of FMD viruses in SEA and China









RRL Pak Chong and NIAH

- Validation of protocols for reduction of AgPath Reagent Used in FMDV Multiplex Real-Time TaqMan Assay (0.6X, total volume 15 μL)
- There was a need to reduce the volume of the reactions as a cost saving investigation
- Under the quality system, this had to be validated to ensure there is no loss in Se and Sp
- RRL Pak Chong kindly agreed to facilitate the live virus lab work







Reduced volume qRT-PCR assay

- Limit of detection test
 - Strong positive
 - Moderate positive

	Strong Positive Sample							
Copy numbers/ml	1X Reaction Mix			0.6X Reaction Mix				
	R1	R2	R3	R1	R2	R3		
1.56E+07	19.09	19.20	19.09	18.34	18.24	18.32		
1.56E+06	24.18	24.14	24.19	23.49	23.49	23.46		
1.56E+05	27.02	26.98	27.02	26.30	26.36	26.36		
1.56E+04	29.00	29.00	29.01	28.31	28.31	28.38		
1.56E+03	31.47	31.62	31.50	31.04	30.97	31.10		
1.56E+02	<mark>33.59</mark>	<mark>33.10</mark>	<mark>33.40</mark>	<mark>33.18</mark>	<mark>33.25</mark>	<mark>33.08</mark>		
1.56E+01	45.00	45.00	<mark>34.98</mark>	45.00	34.22	<mark>34.47</mark>		

Limit of detection approx. 100 copy numbers for both assays

	Moderate Positive Sample								
Copy numbers/ml	1X Reaction Mix			0.6X Reaction Mix					
	R1	R2	R3	R1	R2	R3			
2.98E+04	27.57	27.53	27.56	27.05	27.08	27.02			
2.98E+03	30.81	30.85	30.84	30.59	30.59	30.51			
2.98E+02	<mark>32.13</mark>	<mark>32.14</mark>	<mark>32.05</mark>	<mark>31.92</mark>	<mark>31.78</mark>	<mark>31.64</mark>			
2.98E+01	<mark>35.23</mark>	45.00	<mark>34.28</mark>	<mark>34.54</mark>	<mark>35.47</mark>	<mark>34.79</mark>			

- The assay with reduced volume (0.6x)
 - Was comparable to the standard 1.0x assay
 - Showed no loss in sensitivity
 - Helps reduce the reagent volume by 40% (we can do 16,666 reactions with the same testing budget supplied for 10,000 reactions)







Capacity building

- Capacity building in Lao PDR, Myanmar, Vietnam and RRL-Pak Chong
- Sero surveillance for FMD in goats, Lao PDR 2017-2018 (Manuscript under review)
- Projects impacted due to COVID-19
 - Characterisation of FMDV isolates against commercial vaccine strains
 - NGS analysis and development and validation of real-time serotyping assays







Inactivation of FMD virus in tissue samples

- FMDV in swabs are inactivated at high rate by inactivation buffers
- Little is known about virus inactivation rates in tissue samples
- Collaboration with FLI evaluate inactivation of serotype O and A viruses in tongue epithelium
 - RNAlater
 - RNAShield
- Conclusion: RNA well preserved with both buffers, but long time to reach sufficient inactivation undesirable
- Manuscript published (Horsington et al 2019)
- Further work ongoing





FMD inactivation kinetics

- Studying the inactivation kinetics of FMD under different temperatures and humidity conditions
 - Three temperature (Temp) conditions 10, 20 & 30°C
 - Three Relative Humidity (RH) conditions 80, 60 & 40%
- Virus survival was significantly impacted by increasing temperatures, whereas changes in relative humidity appeared to have less effect
- Continue with this work using different viruses from more serotypes
- Analysis of the data is ongoing and completion of the project was hampered by COVID-19 due to travel restrictions





Vaccine efficacy studies

- Vaccine efficacy studies using serotype A vaccines (A Malaysia 97 and A-GVII vaccines) – a collaboration between CSIRO, WVBR and PI
- A Malaysia 97 vaccine cross-protected cattle challenged with an A-GVII virus of Iranian origin
- However, a newly developed G-VII vaccine did not offer crossprotection when cattle were challenged with an A IRAN-05 lineage virus
- Therefore, it was concluded that G-VII vaccine strain cannot replace A IRAN-05 lineage vaccine strain








Vaccine efficacy studies

- The Intra**D**ermal **A**pplication of **L**iquid (IDAL) device
 - Uses high pressure air to force the vaccine to the skin dermis
- IDL at full dose performed similarly to IM vaccination using ISA206 adjuvant
- The study showed that the IDAL device is a promising alternative to over IM vaccination







Summary

- CSIRO remains committed to work with our partners in SEA to improve FMD control
- Once travel restrictions are lifted, we will plan future visits to the region
- In collaboration with GFRA, EUFMD, SEACFMD and FAO we are planning a virtual scientific FMD conference in December 2020
 - Anybody interested to assist please contact us*

<u>*Wilna.Vosloo@csiro.au</u> Nagendra.Singanallur@csiro.au



This project is supported by Meat & Livestock Australia (MLA), through funding from the Australian Government Department of Agriculture, Water and the Environment as part of its Rural R&D for Profit program, and by producer levies from Australian FMD-susceptible livestock (cattle, sheep, goats and pigs) industries and Charles Sturt University (CSU), leveraging significant in-kind support from the research partners

The research partners for this project are the Commonwealth Science and Industrial Research Organisation (CSIRO), CSU through the Graham Centre for Agricultural Innovation, the Bureau of Meteorology (BOM) and the Australian Department of Agriculture, Water and the Environment, supported by Animal Health Australia (AHA). The project commenced in July 2016 and will conclude in December 2020

IMPROVED SURVEILLANCE, PREPAREDNESS AND RETURN TO TRADE FOR EMERGENCY ANIMAL DISEASE INCURSIONS USING FOOD AND MOUTH DISEASE AS A MODEL

